Optiscan Imaging (ASX:OIL) began its first in-human breast cancer clinical study at the Royal Melbourne Hospital to assess surgical margins in patients receiving treatment for breast cancer using its imaging devices, according to a Monday Australian bourse filing.
The 50-patient study will welcome patients for recruitment for in vivo clinical assessment of breast cancer margins following a lumpectomy procedure. It will use Optiscan's InVue precision surgery and InForm digital pathology imaging devices.
The study completed site initiation.
It will use the data for submissions to the US Food and Drug Administration.
The firm's shares jumped 10% on market close on Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。